

T H Jones

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/10723813/publications.pdf>

Version: 2024-02-01

40
papers

5,818
citations

159585

30
h-index

289244

40
g-index

40
all docs

40
docs citations

40
times ranked

4334
citing authors

#	ARTICLE	IF	CITATIONS
1	Testosterone replacement therapy improves insulin resistance, glycaemic control, visceral adiposity and hypercholesterolaemia in hypogonadal men with type 2 diabetes. <i>European Journal of Endocrinology</i> , 2006, 154, 899-906.	3.7	669
2	Low-Dose Transdermal Testosterone Therapy Improves Angina Threshold in Men With Chronic Stable Angina. <i>Circulation</i> , 2000, 102, 1906-1911.	1.6	560
3	Testosterone Replacement in Hypogonadal Men With Type 2 Diabetes and/or Metabolic Syndrome (the Tj ETQq1 1 0.784314 rgBT /C	8.6	474
4	Clinical and Biochemical Assessment of Hypogonadism in Men With Type 2 Diabetes: Correlations with bioavailable testosterone and visceral adiposity. <i>Diabetes Care</i> , 2007, 30, 911-917.	8.6	438
5	Men with coronary artery disease have lower levels of androgens than men with normal coronary angiograms. <i>European Heart Journal</i> , 2000, 21, 890-894.	2.2	310
6	Testosterone and obesity. <i>Obesity Reviews</i> , 2015, 16, 581-606.	6.5	294
7	Low Testosterone Associated With Obesity and the Metabolic Syndrome Contributes to Sexual Dysfunction and Cardiovascular Disease Risk in Men With Type 2 Diabetes. <i>Diabetes Care</i> , 2011, 34, 1669-1675.	8.6	286
8	Androgens, insulin resistance and vascular disease in men. <i>Clinical Endocrinology</i> , 2005, 63, 239-250.	2.4	256
9	Testosterone replacement in hypogonadal men with angina improves ischaemic threshold and quality of life. <i>Heart</i> , 2004, 90, 871-876.	2.9	218
10	Smoking and hormones in health and endocrine disorders. <i>European Journal of Endocrinology</i> , 2005, 152, 491-499.	3.7	212
11	Low serum testosterone and increased mortality in men with coronary heart disease. <i>Heart</i> , 2010, 96, 1821-1825.	2.9	201
12	Testosterone treatment for men with chronic heart failure. <i>British Heart Journal</i> , 2004, 90, 446-447.	2.1	199
13	The effect of testosterone replacement therapy on adipocytokines and C-reactive protein in hypogonadal men with type 2 diabetes. <i>European Journal of Endocrinology</i> , 2007, 156, 595-602.	3.7	195
14	Testosterone replacement therapy: current trends and future directions. <i>Human Reproduction Update</i> , 2004, 10, 409-419.	10.8	191
15	Testosterone deficiency: a risk factor for cardiovascular disease?. <i>Trends in Endocrinology and Metabolism</i> , 2010, 21, 496-503.	7.1	154
16	Systematic literature review of the risk factors, comorbidities, and consequences of hypogonadism in men. <i>Andrology</i> , 2014, 2, 819-834.	3.5	127
17	Testosterone acts as a coronary vasodilator by a calcium antagonistic action. <i>Journal of Endocrinological Investigation</i> , 2002, 25, 455-458.	3.3	115
18	Gender Differences in the Vasomotor Effects of Different Steroid Hormones in Rat Pulmonary and Coronary Arteries. <i>Hormone and Metabolic Research</i> , 2001, 33, 645-652.	1.5	112

#	ARTICLE	IF	CITATIONS
19	Selective Inhibition of L-Type Ca ²⁺ Channels in A7r5 Cells by Physiological Levels of Testosterone. <i>Endocrinology</i> , 2006, 147, 2675-2680.	2.8	99
20	Erectile dysfunction is associated with low bioactive testosterone levels and visceral adiposity in men with type 2 diabetes. <i>Journal of Developmental and Physical Disabilities</i> , 2007, 30, 500-507.	3.6	75
21	Androgen receptor CAG repeat polymorphism is associated with serum testosterone levels, obesity and serum leptin in men with type 2 diabetes. <i>European Journal of Endocrinology</i> , 2008, 159, 739-746.	3.7	74
22	Statin Therapy Is Associated With Lower Total but Not Bioavailable or Free Testosterone in Men With Type 2 Diabetes. <i>Diabetes Care</i> , 2009, 32, 541-546.	8.6	69
23	INTERLEUKIN-6 SECRETING HUMAN PITUITARY ADENOMAS <i>IN VITRO</i> . <i>Journal of Clinical Endocrinology and Metabolism</i> , 1991, 73, 207-209.	3.6	56
24	Self-administered subcutaneous human menopausal gonadotrophin for the stimulation of testicular growth and the initiation of spermatogenesis in hypogonadotrophic hypogonadism. <i>Clinical Endocrinology</i> , 1993, 38, 203-208.	2.4	48
25	Testosterone for secondary prevention in men with ischaemic heart disease?. <i>QJM - Monthly Journal of the Association of Physicians</i> , 2003, 96, 521-529.	0.5	44
26	Testosterone does not adversely affect fibrinogen or tissue plasminogen activator (tPA) and plasminogen activator inhibitor-1 (PAI-1) levels in 46 men with chronic stable angina. <i>European Journal of Endocrinology</i> , 2005, 152, 285-291.	3.7	42
27	Testosterone: a natural tonic for the failing heart?. <i>QJM - Monthly Journal of the Association of Physicians</i> , 2000, 93, 689-694.	0.5	41
28	Evidence that angiotensin II is a paracrine agent mediating gonadotrophin-releasing hormone-stimulated inositol phosphate production and prolactin secretion in the rat. <i>Journal of Endocrinology</i> , 1988, 116, 367-371.	2.6	40
29	Cardiovascular effects of testosterone: implications of the "male menopause"?. <i>British Heart Journal</i> , 2003, 89, 121-122.	2.1	38
30	Dyslipidaemia is associated with testosterone, oestradiol and androgen receptor CAG repeat polymorphism in men with type 2 diabetes. <i>Clinical Endocrinology</i> , 2011, 74, 624-630.	2.4	37
31	Testosterone deficiency and severity of erectile dysfunction are independently associated with reduced quality of life in men with type 2 diabetes. <i>Andrology</i> , 2014, 2, 205-211.	3.5	28
32	Pharmacokinetics and tolerability of a bioadhesive buccal testosterone tablet in hypogonadal men. <i>European Journal of Endocrinology</i> , 2004, 150, 57-63.	3.7	26
33	Bradykinin stimulates phosphoinositide metabolism and prolactin secretion in rat anterior pituitary cells. <i>Journal of Molecular Endocrinology</i> , 1989, 2, 47-53.	2.5	23
34	The role of androgen receptor CAG repeat polymorphism and other factors which affect the clinical response to testosterone replacement in metabolic syndrome and type 2 diabetes: TIMES2 sub-study. <i>European Journal of Endocrinology</i> , 2014, 170, 193-200.	3.7	19
35	Testosterone inhibits the prostaglandin F ₂ α-mediated increase in intracellular calcium in A7r5 aortic smooth muscle cells: evidence of an antagonistic action upon store-operated calcium channels. <i>Journal of Endocrinology</i> , 2003, 178, 381-393.	2.6	17
36	A new 2% testosterone gel formulation: a comparison with currently available topical preparations. <i>Andrology</i> , 2018, 6, 396-407.	3.5	17

#	ARTICLE	IF	CITATIONS
37	Testosterone replacement therapy. British Journal of Hospital Medicine (London, England: 2005), 2007, 68, 547-553.	0.5	6
38	Effect of the GABA _A Agonist Muscimol on Prolactin Secretion from Human Prolactin-Secreting Adenomas and GH ₃ Rat Pituitary Tumour Cells. Hormone Research, 1992, 37, 113-118.	1.8	4
39	Revascularization with percutaneous coronary intervention does not affect androgen status in males with chronic stable angina pectoris. Andrology, 2016, 4, 486-491.	3.5	2
40	The consensus recommendations of a group of international experts on the fundamental concepts related to the issues of testosterone deficiency and its treatment.. Obesity and Metabolism, 2016, 13, 15-31.	1.2	2